---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-043384"
form_type: "8-K"
ticker: "SSII"
cik: "0001676163"
company_name: "SS Innovations International, Inc."
filed_at: "2025-05-14T23:59:59+00:00"
generated_at: "2026-05-21T08:59:21.959532+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# SS Innovations Q1 revenue $5.1M (+40.8% YoY); net loss narrows; FDA submission planned by July 2025

## Summary
- Revenue $5.1M (+40.8% YoY); gross margin 21.23% (up 121 bps); net loss $5.7M ($0.03 diluted) vs $9.8M ($0.06) in Q1 2024.
- SSi Mantra installations 15 in Q1 (+66.7%), cumulative installed base 78, cumulative surgeries 3,568.
- Cash $15.9M, zero long-term debt; subsequently uplisted to Nasdaq on April 25, 2025.
- Plan to submit De Novo FDA application for SSi Mantra by July 2025; CE Mark possible late 2025.
- Achieved world's first robotic cardiac telesurgery; gained regulatory approvals in Philippines and Ukraine.

## SEC filing metadata
- accession: 0001213900-25-043384
- form_type: 8-K
- ticker: SSII
- cik: 0001676163
- company_name: SS Innovations International, Inc.
- filed_at: 2025-05-14T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1676163/000121390025043384/0001213900-25-043384-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1676163/000121390025043384/ea0242229-8k_ssinnov.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-043384
- JSON: https://secwatch.observer/filing/0001213900-25-043384.json
- Plain text: https://secwatch.observer/filing/0001213900-25-043384.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.